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ABSTRACT
Acinetobacter baumanii is an opportunistic bacterium that causes widespread nosocomial infections and tends to be 
multi-resistant to most of antibiotics. Tigecycline is a well-known antibiotic that possesses a wide-range of activities 
and is very active in vitro towards a variety of resistant pathogens, including A. baumanii. The aim of this study was 
to evaluate the effects of the imipenem and tigecycline combination against carbapenem-resistant A. baumanii (CRAB). 
The minimal inhibitory concentration (MIC) was determined using the E-test method. The microbroth checkerboard 
technique was employed to determine the effects of the imipenem and tigecycline interaction by obtaining the fractional 
inhibitory concentration (FIC) index value. A time kill (TK) study was performed to identify any synergistic effects when 
both imipenem and tigecycline were used against CRAB strains. The result demonstrated that all A. baumanni strains 
exhibited imipenem MIC values of 32 µg/mL. The combination of imipenem and tigecycline demonstrated an additive 
effect (FIC > 0.5-4) against all of the strains and synergistic activity (decrement of > 2 log10 CFU/mL) towards AC 34/07 
and AC 32/06 strains. The use of imipenem in combination with tigecycline resulted in a more efficient activity and an 
increased capability to control CRAB infections. This effect showed potential combination and may be of importance in 
the development or modification of antimicrobial agents for the treatment of CRAB infections.
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ABSTRAK
Acinetobacter baumanii adalah bakteria oportunis yang menyebabkan jangkitan nosokomial secara meluas dan 
cenderung untuk menjadi multirintang terhadap kebanyakan antibiotik. Tigecycline adalah antibiotik yang mempunyai 
pelbagai aktiviti dan sangat aktif secara in vitro terhadap pelbagai patogen rintang antibiotik, termasuklah A. baumanii. 
Tujuan kajian ini adalah untuk menilai kesan dan gabungan antibiotik imipenem dan tigecycline terhadap A. baumanii 
rintang-karbapenem (CRAB). Kepekatan perencatan minimum (MIC) ditentukan dengan menggunakan kaedah E-test. 
Teknik papan penyemak mikrokaldu digunakan untuk menentukan kesan imipenem dan interaksinya dengan tigecycline 
dengan mendapatkan nilai indeks kepekatan rencatan berperingkat (FIC). Ujian masa membunuh (TK) telah dijalankan 
untuk mengenal pasti kesan sinergi apabila kedua-dua imipenem dan tigecycline digunakan terhadap strain CRAB. Hasil 
ujian menunjukkan bahawa semua strain A. baumanni memberi nilai imipenem MIC sebanyak 32 μg/mL. Gabungan 
imipenem dan tigecycline menunjukkan kesan tambahan (FIC> 0,5-4) terhadap semua strain yang diuji dan aktiviti sinergi 
(pengurangan sebanyak> 2 log10 CFU/mL) terhadap strain AC 34/07 dan AC 32/06. Penggunaan kombinasi imipenem 
dan tigecycline menghasilkan aktiviti yang lebih cekap dan meningkatkan kemampuan untuk mengawal jangkitan CRAB. 
Kesan ini menunjukkan kombinasi yang berpotensi dan mungkin penting dalam pembangunan atau pengubahsuaian 
agen antimikrob untuk rawatan jangkitan CRAB.
Kata kunci: Acinetobacter baumani; imipenem I; rintang-karbapenem; tigecycline
INTRODUCTION
A. baumanii is an opportunistic pathogen and associated 
with a variety of nosocomial infections worldwide. These 
nosocomial infections include pneumonia, urinary tract 
infection and septicemia which occur most frequently 
in patients who are being treated in the intensive care 
unit (ICU) (Al-Dabaibah et al. 2012; Chaaria et al. 2013; 
Tsakiridou et al. 2014). A. baumanii causes serious 
bacteremia infections and an increased mortality rate of 
49% when resistance towards the main standard antibiotic 
carbapenem is present. These strains are referred to as 
carbapenem-resistant A. baumanii (CRAB) and they exhibit 
resistance towards most drugs, including β-lactams, 
aminoglycosides and fluoroquinolones (Bonomo & Szabo 
2006).
 The management of an A. baumanii multi-resistant 
infection is medical concern because of limited therapeutic 
options available and can be complicated, due to the 
emergence of carbapenem-resistant isolates (Bou et al. 
2000). Treatment of CRAB poses a problem for modern 
1062 
medicine worldwide and is challenging to the physicians. 
It has been proposed that combinations of different 
antibiotics should be administered to create an active 
treatment and prevent the emergence of resistance (Peleg 
et al. 2008). The activity of an antimicrobial agent can 
sometimes be enhanced by its use in combination with 
another agent with a different mode of action. Various 
antibiotic combinations such as polymyxin and imipenem, 
rifampicin or azithromycin, as well as other combinations, 
have been studied to determine whether they exhibit a 
synergistic effect against CRAB (Lim et al. 2011; Wareham 
& Bean 2006; Yoon et al. 2004). Some studies have shown 
that the in vitro synergy of antibiotic combinations may 
be strain dependent (Lim et al. 2011; Wareham & Beam 
2006). However, the use of antibiotic combination for the 
practical treatment of CRAB infections is still controversial.
 Tigecycline has been shown to possess a wide 
spectrum of antibiotic activity against many pathogens 
in vitro, including A. baumanii (Castanheira et al. 2008). 
The combination of tigecycline with other antibiotics such 
as imipenem, has shown synergistic antibacterial activity 
and could be valuable for the treatment of infectious CRAB. 
Thus, in this study, tigecycline is investigated to determine 
its potential activity against CRAB strains when combined 
with imipenem.
MATERIALS AND METHODS
BACTERIAL ISOLATES
Fifty clinical isolates of CRAB were obtained from the 
Microbiology and Immunology Laboratory, Universiti 
Kebangsaan Malaysia Medical Centre (UKMMC) in the 
year 2006. The isolates were identified using the API 20NE 
system (Bio-Merieux, Marcy I’Etoile France). The isolates 
were stored at -80°C in Mueller-Hinton broth containing 
15% glycerol.
ANTIMICROBIAL AGENTS
Antimicrobial agents were purchased from companies 
as standard reference powders for laboratory use. The 
following antimicrobial agents were tested: Imipenem 
(Sigma-Aldrich, German) and tigecycline (Sigma-Aldrich, 
UK).
SUSCEPTIBILITY TESTING
The MICs of the 50 bacterial isolates for both imipenem 
and tigecycline were determined by the E-test method, 
using commercially available E-test strips (Bio-Me´rieux, 
France). Bacterial suspensions containing approximately 
105 colony-forming units (CFU) were inoculated onto 
Mueller-Hinton agar plates. Then, E-test strips were 
placed on top of the inoculated agar plates. The plates 
were then incubated at 35±2°C for 18-20 h. The MIC 
was defined as the lowest concentration of antimicrobial 
agent that completely inhibited the bacterial growth. The 
concentrations of imipenem and tigecycline that were 
tested against all of the strains ranged from 0.002 to 32 
μg/mL and 0.016 to 256 μg/mL, respectively. Escherichia 
coli ATCC 25922 were used as a control for each test. The 
breakpoint for imipenem susceptibility was interpreted to 
be ≤ 4 μg/mL, 8 μg/mL and ≥ 16 μg/mL for susceptible, 
intermediate and resistant, respectively (CLSI 2011). 
Because there is no approved standard for classifying A. 
baumanii as susceptible or resistant to tigecycline, the 
provisional MIC breakpoints used for this agent were ≤ 
2 μg/mL, 4 μg/mL and ≥ 8 μg/mL, which designated as 
susceptible, intermediate and resistant, respectively (Wyeth 
Research, personal communication).
CHECKERBOARD ANALYSIS
The checkerboard method was used to assess the activity 
of the antimicrobial combinations (Petersen et al. 2006). 
Imipenem and tigecycline solution were combined in the 
form of a checkerboard in a 96-well microtiter plate. Each 
antimicrobial agent was prepared in a fixed volume of 50 
μL (a total volume of 100 μL for two antimicrobial agents) 
and 100 μL of bacterial suspension was then added to each 
well. The final concentration of the bacterial suspension 
was approximately 5 × 105 CFU/mL in a total volume of 200 
μL in each well. The microtiter plate was then incubated 
at 35±2°C for 18-24 h. After the overnight incubation, 
the MIC values were determined. Positive (with bacteria) 
and negative controls (without bacteria) were analyzed 
simultaneously. The fractional inhibitory concentration 
(FIC) index for each antibiotic was determined by dividing 
the concentration of a particular antibiotic necessary to 
inhibit growth in a given row by the MIC of the antibiotic 
alone. The FIC index was calculated by adding the separate 
FICs for each of the drugs present in a particular well. 
Interpretation of the FIC index was as follows: FIC index ≤ 
0.5, synergy; FIC index > 0.5-4, additive; FIC index > 4.0; 
antagonistic (Eliopoulos & Moellering 1991).
TIME-KILL ASSAY
A time-kill study was done to assess the synergistic 
combinations of the drugs (Petersen et al. 2006). The 
antimicrobial agents were tested at concentrations of 1, 
1/2 and 1/4 × MIC (sub-inhibitory concentrations) with a 
starting inoculum of 5 × 105 CFU/mL prepared in Mueller-
Hinton broth Sample aliquots (10 μL) were removed 
from cultures at 0, 2, 4, 8 and 24 h. Antimicrobial activity 
was ascertained by serial dilution (10- to 10,000-fold) of 
plated samples. Growth control wells for each organism 
were prepared without antimicrobial agent and performed 
in parallel to the antimicrobial test tubes. Synergy of a 
combination of antibiotics was defined as a decrease of at 
least 2 log10 CFU/mL at 24 h compared to the single most active drug in combination (Domaracki et al. 2000). An 
antibiotic or its combination was considered bactericidal 
when it produced a reduction of at least 3 log10 CFU/mL from starting inoculum at 4 or 24 h post incubation (Rand 
& Houck 2004).
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RESULTS
SUSCEPTIBILITY TESTING
The MIC values for imipenem and tigecycline were 
shown in Table 1. All isolates were resistant to imipenem 
(MIC at 32 μg/mL). As for tigecycline, 45 isolates were 
susceptible with MIC values ranging from 2 to 4 μg/mL 
and 5 isolates were intermediate with MIC value of 6 μg/
mL. The CRAB isolates (AC 04/07, AC 34/07, AC 32/06 and 
AC 09/07 strains) that exhibited the lowest MIC value (2 
μg/mL) for tigecycline were subsequently analyzed by the 
checkerboard method and the time-kill assay to determine 
their sensitivity to synergistic effects of the tigecycline and 
imipenem combination.
antimicrobial combination exhibited no synergistic effects 
toward strain AC 04/07 at 0.5 × MIC for imipenem and 0.25 
× MIC for tigecycline, or toward strain AC 09/07 at 0.25 × 
MIC for imipenem and 0.5 × MIC for tigecycline.
DISCUSSION
Infections caused by CRAB have increased tremendously 
and the struggle to treat these infections has been 
complicated by the development of resistance towards a 
variety of antibiotics, including β-lactams, aminoglycosides 
and fluoroquinolones, by various isolates (Fishbain 
& Peleg 2010; Garnacho-Montero & Amaya-Villar 
2010). Aggressive treatment with two antimicrobial 
agents possessing synergistic activity has been shown to 
increase positive outcomes in the treatment of immune-
compromised patients with CRAB-related infections (Kuo et 
al. 2008; Lee et al. 2007). The results of this study showed 
the presence of synergistic activity between imipenem and 
tigecycline. Tigecycline is a bacteriostatic agent (Pachon-
Ibanez et al. 2004) used to treat A. baumanii infections, 
including CRAB (Henwood et al. 2002). In this study, 
tigecycline is more active than imipenem against CRAB. 
Tigecycline possesses wide-spectrum antibiotic activity 
and is very active in vitro against almost all pathogens, 
including A. baumanii (Castanheira et al. 2008; Fritsche et 
al. 2005). Due to the bacteriostatic activity of tigecycline 
against CRAB, it is appropriate to combine this drug with 
another antimicrobial agent, such as imipenem (Pachon-
Ibanez et al. 2004; Scheetz et al. 2007), to improve the 
outcome of a patient’s treatment. The in vitro results of this 
study have demonstrated that the imipenem and tigecycline 
combination is effective against CRAB and that a maximum 
synergistic effect can be observed over time using this 
combination treatment.
 The checkerboard method and time-kill analysis 
have been used globally to investigate the in vitro activity 
of an antimicrobial combination against various types 
of resistant pathogens (Lee et al. 2007; Petersen et al. 
2006; Scheetz et al. 2007). However, there was a slight 
difference observed in the results that were obtained 
by both methods; all four of the isolates exhibited an 
additive effect according to the checkerboard method, but 
demonstrated synergistic activity according to the time-kill 
analysis. Based on these observations, it was postulated 
TABLE 1. Susceptibility of the 50 CRAB isolates towards 
imipenem and tigecycline antibiotics
Antibiotic MIC (μg/mL) No. of isolates (%)
Imipenem
Tigecycline
32
2
3
4
6
50 (100)
4 (8)
21 (42)
20 (40)
5 (10)
CHECKERBOARD ANALYSIS
The results from the checkerboard analysis of the 
imipenem/tigecycline combination are shown in Table 
2. All four isolates demonstrated an additive sensitivity 
with FIC > 0.5-4. No antagonistic interaction (FIC ≥ 4) 
was observed.
TIME-KILL ANALYSIS
In the time-kill assay (Table 3), the imipenem and 
tigecycline combination at 0.25 × MIC for imipenem and 
1 × MIC for tigecycline produced a synergistic activity 
towards strain AC 34/07 at the 24-h time point. Likewise, 
the combination of the imipenem and tigecycline 
exhibited a synergistic effect against strain AC 32/06 at 
the 2-, 4- and 6-h time points, at a concentration of 0.5 
× MIC for imipenem and 0.25 × MIC for tigecycline. The 
synergistic effect was demonstrated by a reduction in the 
bacterial colony count of ≥ 2 log10 CFU/mL. However, this 
TABLE 2. Fractional inhibitory concentration (FIC) values for the 
imipenem/tigecycline combination towards CRAB isolates
A. baumanii 
isolates
Combination MIC (μg/mL) Individual FIC values FIC index
Imipenem (I) Tigecycline (T) FIC(I) FIC(T) FIC(I) + FIC(T)
AC 04/07
AC 34/07
AC 32/06
AC 09/07
16
8
16
8
0.5
3
1
3
0.5
0.25
0.5
0.25
0.25
1
0.25
0.5
0.75 (Ad)
1.25 (Ad)
0.75 (Ad)
0.75 (Ad)
Ad = additive interaction
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that the time-kill method was more sensitive than the 
checkerboard method in detecting synergy. The additive 
interactions that were observed were not affected by the 
strains’ individual susceptibility to tigecycline. However, 
these interactions resulted in an increase in imipenem 
activity from antagonistic effect to an additive effect. The 
end result for the antimicrobial combinations against all 
four of the CRAB isolates indicated that the MIC value for 
imipenem decreases from its individual MIC value of ≥ 32 
to 8 μg/mL and 16 μg/mL when it is used in combination 
with tigecycline. This outcome proves that in the presence 
of another type of antimicrobial agent, such as tigecycline, 
the susceptibility of CRAB to β-lactam antibiotic increases.
 The development of resistance to tigecycline among 
CRAB has been reported with resistance rates ranging 
between 9.5 and 66% (Lolans et al. 2006; Navon-Venezia 
et al. 2007). This was usually observed when tigecycline 
was used as monotherapy for treatment of CRAB infections 
(Karageorgopoulos et al. 2008). Combination therapy 
with several classes of antibiotics used for the treatment 
of carbapenamase-producing Gram-negative infections 
has shown greater activity and delayed development of 
resistance (Rahal et al. 2002). As shown in this study, 
combination therapy is more effective against CRAB. 
However, the synergistic effect of each antibiotic is 
specific to each clinical isolates as shown by 2 out of 4 
strains tested. This shows that the combination treatment 
efficacy may vary for every single strain (Carmeli et al. 
2010). Combination therapy should be the preferred choice 
of treatment as it improves the possibility of achieving a 
synergistic effect and helps to overcome the development 
of resistance.
 In conclusion, this in vitro study reporting that the 
combination of tigecycline with other antimicrobial agents 
can be used to achieve a better treatment of infections 
caused by CRAB strains. In addition, the imipenem and 
tigecycline combination promises to be useful for the 
treatment of CRAB infections.
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